Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure

被引:27
|
作者
Watanabe, H
Kakihana, M
Ohtsuka, S
Sugishita, Y
机构
[1] KINU Med Assoc Hosp, Dept Cardiol, Mitsukaido City, Ibaraki 3030016, Japan
[2] Ibaraki Prefectural Univ Hlth Sci, Ami, Ibaraki, Japan
[3] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Cardiovasc, Tsukuba, Ibaraki 305, Japan
关键词
D O I
10.1016/S0735-1097(98)00392-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure, Background. The attenuation of cyclic guanosine 5'-monophosphate (cGMP) production due to inactivation of guanylate cyclase by increased superoxide has been reported as a mechanism of nitrate tolerance. Carvedilol has been known to combine alpha/beta-blockade with antioxidant properties. Methods. To evaluate the effect of carvedilol on nitrate tolerance, 40 patients with chronic heart failure were randomized to four groups that received either carvedilol (2.5 mg once a day [carvedilol group, n = 10]), metoprolol (30 mg once a day [metoprolol group, n = 10]), doxazosin (0.5 mg once a day [doxazosin group, n = 10]) or placebo (placebo group, n = 10), Vasodilatory response to nitroglycerin (NTG) was assessed with forearm plethysmography by measuring the change in forearm blood flow (FBF) before and 5 min after sublingual administration of 0.3 mg NTG, and at the same time blood samples were taken from veins on the opposite side to measure platelet cGMP, Plethysmography and blood sampling were obtained serially at baseline (day 0); 3 days after carvedilol, metoprolol, doxazosin or placebo administration (day 3); and 3 days after application of a 10-mg/24-h NTG tape concomitantly with carvedilol, metoprolol, doxazosin or placebo (day 6), Results. There was no significant difference in the response of FBF (%FBF) and cGMP (%cGMP) to sublingual NTG on day 0 and day 3 among the four groups. On day 6, %FBF and %cGMP were significantly lower in the metoprolol, doxazosin and placebo groups than on day 0 and day 3, but these parameters in the carvedilol group were maintained. Conclusions. These results indicated that carvedilol may prevent nitrate tolerance in patients with chronic heart failure during continuous therapy,vith NTG. (C) 1998 by the American College of Cardiology.
引用
收藏
页码:1194 / 1200
页数:7
相关论文
共 50 条
  • [21] BENEFITS AND HAZARDS OF CARVEDILOL IN UNSTABLE ANGINA - A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY
    ZEHENDER, M
    FABER, T
    SCHNABEL, P
    KECK, A
    JERON, A
    GREVE, D
    JUST, H
    [J]. CIRCULATION, 1995, 92 (08) : 92 - 92
  • [22] Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance
    Watanabe, H
    Kakihana, M
    Ohtsuka, S
    Sugishita, Y
    [J]. CIRCULATION, 1997, 96 (08) : 2545 - 2550
  • [23] A PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF NEUCARDIN™ IN PATIENTS WITH CHRONIC HEART FAILURE
    Gao, Runlin
    Zhang, Jian
    Liu, Heping
    Wang, Lina
    Pang, Xiaohua
    Fu, Lu
    Meng, Fanbo
    Zhou, Mingdong
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 668 - 668
  • [24] A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure
    Xian, Shaoxiang
    Yang, Zhongqi
    Lee, Jun
    Jiang, Zhiping
    Ye, Xiaohan
    Luo, Luyi
    Jin, Lili
    Yang, Tianlun
    Ye, Suilin
    Lu, Dongfeng
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2016, 186 : 136 - 142
  • [25] Inorganic Nitrate in Angina Study: A Randomized Double-Blind Placebo-Controlled Trial
    Schwarz, Konstantin
    Singh, Satnam
    Parasuraman, Satish K.
    Rudd, Amelia
    Shepstone, Lee
    Feelisch, Martin
    Minnion, Magdalena
    Ahmad, Shakil
    Madhani, Melanie
    Horowitz, John
    Dawson, Dana K.
    Frenneaux, Michael P.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (09):
  • [26] Randomized, Placebo-Controlled, Double-Blind Study of Ropinirole in Chronic Stroke
    Cramer, Steven C.
    Dobkin, Bruce H.
    Noser, Elizabeth A.
    Rodriguez, Rachelle W.
    Enney, Lori A.
    [J]. STROKE, 2009, 40 (09) : 3034 - 3038
  • [27] Randomized, Double-Blind, Placebo-Controlled Study of Sitaxsentan to Improve Impaired Exercise Tolerance in Patients With Heart Failure and a Preserved Ejection Fraction
    Zile, Michael R.
    Bourge, Robert C.
    Redfield, Margaret M.
    Zhou, Duo
    Baicu, Catalin F.
    Little, William C.
    [J]. JACC-HEART FAILURE, 2014, 2 (02) : 123 - 130
  • [28] A randomized, double-blind, placebo-controlled phase II study of ularitide in patients with decompensated congestive heart failure
    Mitrovic, V
    Seferovic, P
    Simeunovic, D
    Miric, M
    Moiseyev, VS
    Kobalava, Z
    Nitsche, K
    Forssmann, WG
    Luss, H
    Meyer, M
    [J]. JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S151 - S151
  • [29] Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure
    Rector, TS
    Bank, AJ
    Mullen, KA
    Tschumperlin, LK
    Sih, R
    Pillai, K
    Kubo, SH
    [J]. CIRCULATION, 1996, 93 (12) : 2135 - 2141
  • [30] Chinese herbal medicine for chronic heart failure:a multicenter, randomized,double-blind, placebo-controlled trial
    Liangtao Luo
    Juan Wang
    Aiqing Han
    Peng Zhang
    Shuzhen Guo
    Chan Chen
    Xuegong Xu
    Qian Lin
    Huihui Zhao
    Wei Wang
    [J]. Journal of Traditional Chinese Medical Sciences, 2014, 1 (02) : 98 - 108